OncoMatch/Clinical Trials/NCT07258836
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Is NCT07258836 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LY4214835 for neoplasms.
Treatment: LY4214835 — The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: systemic cancer therapy
documented disease progression on standard-of-care treatment (for example, failure of chemotherapy, targeted therapy or immunotherapy)
Lab requirements
Cardiac function
No history of risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome); No marked baseline prolongation of QT/QTc interval (e.g., QTc > 450 ms)
Have a history of risk factors for Torsades de Pointes (for example, heart failure, hypokalemia, family history of Long QT Syndrome); Have a marked baseline prolongation of QT/corrected QT interval (QTc) interval (for example, repeated demonstration of a QTc interval greater than (>) 450 millisecond (ms)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Invicro · New Haven, Connecticut
- Boston Medical Center · Boston, Massachusetts
- Massachusetts General Hospital (MGH) · Charlestown, Massachusetts
- BAMF Health Inc. · Grand Rapids, Michigan
- Ichor Research · Syracuse, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify